FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
Variance for IVD's - Approval of an Alternative Requirement of the User Labeling - Requirements for Devices that Contain Dry Natural Rubber |
September 10, 1999
Ms. Carolyn D. Jones, J. D
Associate Vice President
Technology and Regulatory Affairs
HIMA
1200 G Street, NW, Suite 400
Washington, D.C. 20005
Re: Docket #99P-1720/CP 1
Dear Ms. Jones:
This is in response to your petition dated June 3, 1999, requesting a variance from the requirements of the labeling regulation for natural rubber-containing medical devices, incorporated in 21 CFR 801.437.
Specifically, your petition requested that manufacturers of in vitro diagnostic devices (IVDs) be allowed to omit the statement "This Product Contains Dry Natural Rubber," from the label on the vials of these products. The variance is being sought for those products that have vial labels that are too small to accommodate the required statement and that provide the required information on an outer package as well as in a package insert.
The request is based on the insufficiency of space on the labels for IVD vials and on the precedent that FDA established by granting a similar variance to an individual manufacturer of these devices, Bio-Rad Laboratories. The current petition seeks to expand the variance granted to Bio-Rad into a general variance that includes other IVD manufacturers that are in a similar situation. The petition argues that both FDA and industry resources would be conserved by issuing such a variance.
The agency agrees with HIMA, and is hereby granting a general variance to manufacturers of in vitro diagnostic devices from the requirements of 21 CFR 801.437(e) with respect to the location of the warning statement on the immediate device package (vial) label. This variance is based on an insufficiency of label space on the vial label, and the availability of adequate warning statements on the outer package and package insert in accordance with 21 CFR 809.10 and 21 CFR 801.437.
Any manufacturer of an in vitro diagnostic device who wishes to apply this generic variance to their specific products must employ the following criteria:
The agency intends to announce the availability of this variance in the Federal Register in the near future. Thank you for your continued interest in this matter. We trust this response has been helpful.
Sincerely yours, David Feigal, M.D |
Updated January 25, 2000
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH